Meeting
2011 ASCO Annual Meeting
A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501).
Authors
V. A. Morrison
VA Medical Center, Minneapolis, MN
V. A. Morrison , S. Jung , J. L. Johnson , J. Leonard , B. D. Cheson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session
Track
Special Sessions,Clinical Trials
Sub Track
Lymphoma
Clinical Trial Registration Number
NCT 00553644
Citation
J Clin Oncol 29: 2011 (suppl; abstr TPS223)
Abstract #
TPS223
Poster Bd #
51E
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: Results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).
First Author: Cyrille Touzeau
Poster
2022 ASCO Annual Meeting
A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
First Author: Andrew J Yee
Poster
2020 ASCO Virtual Scientific Program
Lenalidomide plus R-GDP (R2-GDP) in relapsed/refractory diffuse large B-cell lymphoma: Final results of the R2-GDP-GOTEL trial.
First Author: Luis De La Cruz Merino Sr.
Poster
2018 ASCO Annual Meeting
Long term follow-up (FU) of lenalidomide plus R-CHOP therapy in patients with newly diagnosed diffuse large b-cell lymphoma (DLBCL): Combined analysis from two phase 2 trials.
First Author: Alessia Castellino